Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS2543 in advanced tumors
NCT05068856Phase 1Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS2543 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Dec 2021; status: terminated.
02
Drugs
HRS2543
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05068856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068856.